Apollon Wealth Management LLC Has $675,000 Holdings in STERIS plc (NYSE:STE)

Apollon Wealth Management LLC decreased its holdings in shares of STERIS plc (NYSE:STE) by 5.1% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 2,783 shares of the medical equipment provider’s stock after selling 149 shares during the period. Apollon Wealth Management LLC’s holdings in STERIS were worth $675,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Quent Capital LLC raised its position in shares of STERIS by 112.7% during the 1st quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 71 shares during the last quarter. Empowered Funds LLC lifted its stake in STERIS by 52.1% in the first quarter. Empowered Funds LLC now owns 1,729 shares of the medical equipment provider’s stock valued at $389,000 after buying an additional 592 shares during the period. Headlands Technologies LLC bought a new position in STERIS during the first quarter worth about $36,000. Russell Investments Group Ltd. grew its position in shares of STERIS by 8.3% during the 1st quarter. Russell Investments Group Ltd. now owns 58,841 shares of the medical equipment provider’s stock worth $13,235,000 after buying an additional 4,494 shares during the period. Finally, TIAA Trust National Association increased its stake in shares of STERIS by 15.6% in the 1st quarter. TIAA Trust National Association now owns 1,798 shares of the medical equipment provider’s stock valued at $404,000 after acquiring an additional 242 shares during the last quarter. 94.69% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the transaction, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at approximately $10,603,710. This represents a 35.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.14% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on STE shares. StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. JMP Securities reissued a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a report on Wednesday, August 7th. Stephens restated an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research report on Thursday, November 7th. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research note on Friday, November 8th. Finally, KeyCorp raised their price target on STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.00.

STERIS Stock Performance

STE opened at $220.12 on Friday. The company has a market capitalization of $21.73 billion, a price-to-earnings ratio of 50.26 and a beta of 0.85. The business’s 50-day moving average price is $230.77 and its two-hundred day moving average price is $228.15. STERIS plc has a 1 year low of $195.47 and a 1 year high of $248.24. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. The business had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.33 billion. STERIS had a return on equity of 13.78% and a net margin of 8.02%. STERIS’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.03 EPS. Equities analysts expect that STERIS plc will post 9.15 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be paid a $0.57 dividend. The ex-dividend date of this dividend is Tuesday, November 19th. This represents a $2.28 annualized dividend and a yield of 1.04%. STERIS’s payout ratio is currently 52.05%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.